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Abstract
Hypertension is one of the main causes of mortality and morbidity in Indonesia. Resistant hypertension is a case 
of hypertension whose blood pressure remains high, after a change in lifestyle and obtaining management of 3 
anti-hypertensive drugs with optimal doses with a different mechanism of action. The exact prevalence of HR is 
not known with certainty. The lack of data on the prevalence of resistant hy- pertension is the aim of this study to 
complete the data on the prevalence of resistant hypertension in UKI General Hospital. This research is descriptive. 
Data is taken from UKI General Hospital medical records from January to December 2019 with inclusion and 
exclusion criteria. Of the 1,030 in patients with hy- pertension, 139 patients are suffering from resistant hypertension. 
With the number of men and women not very different, the average age is 58 years and most cases are in the age 
group> 65 years. Chronic kidney failure (CKD) is the most common comorbid disease, followed by DM and heart 
failure. Patients with more resistant hypertension have very high initial blood pressure, and most use a combination 
of 3 drugs to control their blood pressure.
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1. Definition of Resistant Hypertension
Resistant Hypertension is a case 
of hypertension whose blood pressure 
remains high, the measurement is 
carried out by Ambulatory Blood 
Pressure Monitoring or Home Blood 
Pressure Monitoring, after lifestyle 
changes and receiving management 
of 3 anti-hypertensive drugs 
with optimal doses with different 
mechanisms of action, usually 
including long acting calcium 
channels. blockers, Angiotensin 
Receptor Blockers / Angiotensin 
Converting Enzym inhibitors, and 
Diuretics. 5,6
2. Prevalence of Resistant 
Hypertension
The exact number of cases of 
resistant hypertension is currently 
unknown. .5,6,7,8   The prevalence of 
resistant hypertension varies widely, 
ranging from 5.56% in studies 
conducted in France to 34.32% 
in studies conducted in England 
and Scandinavia. According to 
Rossignol et al, the incidence of 
resistant hypertension is 0.5% - 
14% of the total patients receiving 
antihypertensive therapy. Based on 
these data, it was found that only 
50% of resistant hypertension cases 
received the optimal drug and dose, 
while the other 40% were due to non-
compliance.
 patients taking medication 
or developing “white coat 
hypertension.” 8 Using a lowered 
blood pressure threshold can increase 
the prevalence rate of resistant 
hypertension by 4% . 9
Background
Hypertension is one of the main causes 
of mortality and morbidity in Indonesia, 
so the management of this disease is very 
important to do at various levels of health 
facilities. 1 
A person will be considered hypertensive 
if they have systolic blood pressure ≥ 140 
mmHg and or diastolic blood pressure ≥ 90 
mmHg, on repeated examinations. 1
According to The Seventh Report of the 
Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC-7) guidelines in 
2003, resistant hypertension (HR) is defined 
as failure to achieve blood pressure targets.
Left ventricular hypertrophy (LVH), 
heart failure, myocardial infarction, stroke, 
retinopathy, microalbuminuria and chronic 
kidney disease are target organ damage 
that can be at a higher risk of occurring in 
patients with resistant hypertension than in 
controlled hypertensive patients. 2
The exact prevalence of HR is not 
well known. Some studies suggest a HR 
prevalence of 5% to 50% in general practice, 
or higher in nephrology clinics, including 
patients with CKD.3
Resistant hypertension almost always has 
a multifactorial etiology. The management 
of HR begins with the identification and 
modification of lifestyle factors, ensuring 
medication adherence, stopping drugs that 
can cause an increase in blood pressure, 
treating secondary causes of hypertension, 
and using effective drugs to control blood 
pressure. . 3,4
The lack of data on the prevalence of 
resistant hypertension is the background of 
this study, in order to add to the primary data 
on the prevalence of resistant hypertension 
in Indonesia, especially at UKI Hospital.
3
coat hypertension” and medication 
non-adherence. Furthermore, the 
management of resistant hypertension 
begins with lifestyle modifications, 
ensuring patient adherence to 
treatment, treating secondary causes 
that can lead to increased blood 
pressure, stopping the consumption of 
drugs that can increase blood pressure 
and optimizing the antihypertensive 
drugs given. Lifestyle modification 
is carried out by limiting the amount 
of salt consumed (<2400 mg / 
day), sleeping regularly> 6 hours 
a day, exercising, losing weight, 
quitting smoking, stopping alcohol 
consumption and regularly taking the 
antihypertensive drugs that are given. 
Antihypertensive drugs given to 
patients with resistant hypertension 
include 3 main types of drugs, namely 
ACE-inhibitors, CCBs and diuretics 
with a maximum tolerable dose. .6
Blood pressure that has not 
been controlled by the first step 
management will go to the next step, 
namely replacing the thiazide drugs 
used to be chlortiadone or indapamide. 
If still not reaching the target, the 
use of mineralocorticoid receptor 
antagonist drugs (spironolactone or 
eplerenone) can be started. When
 still not reaching the target after 
receiving mineralocorticoid receptor 
antagonist drugs, the next fourth step 
is administration of beta blockers 
or administration of central alpha 
agonists if beta blocker drugs are 
contraindicated. If after the fourth 
step management has not reached 
the target, hydralazine drugs can be 
given. The last step that can be given 
if it still has not reached the target is 
replacing hydralazine with minoxidil. 
Management of steps four to six is 
only based on expert opinion. .6
3. Factors Affecting Resistance 
Hypertension
Hypertension resistance can 
be influenced by several factors, 
for example demographic factors, 
comorbidities, consumption of drugs 
that can raise blood pressure.
  Demographic factors for resistant 
hypertension: Age> 75 years, 
Obesity, race, black skin, excessive 
sodium intake, very high initial 
blood pressure, uncontrolled 
chronic hypertension.
  Comorbidities associated 
with resistant hypertension: 
Hypertension Mediated Organ 
Damage (Left Ventricular 
Hypertrophy and / or Chronic 
Kidney Diseases), Diabetes, 
Coronary artery disease, Peripheral 
vascular disease, Cerebro vascular 
disease, Congestive heart failure, 
Atrial fibrilation, Albuminuria, 
Aortic Stiffening , Isolated 
systolic hypertension, Primary 
hyperaldosteronism, renovascular 
atherosclerosis disease, Sleep 
apnea, Phaeochromocytoma, 
aortic coarctation, Cushing 
disease, Hyperparatioroid.
  Take drugs that can increase blood 




Erythropoietin, Steroids, Cancer 
Treatment, Cocaine, Amphetamine
4. Management of Resistant 
Hypertension
The first step in treatment of 
resistant hypertension is to rule out 
other possibilities such as “white 
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the age interval 26 - 35 years, 36 - 45 years, 
46 - 55 years, 56 - 65 years and> 65 years.
At the age of 26-35 years, there were 
8 patients (5.8%), aged 36 - 45 years, there 
were 15 patients (10.8%), there were 28 
aged 46 - 55 years patients (20.1%), aged 
56-65 years were present
There were 45 patients (30.9%) and 
aged> 65 years (32.4%) with a mean age of 
58 years.
Patients with resistant hypertension who 
were admitted to the UKI Hospital had 30 
patients (21.6%) of initial blood pressure 
classified as grade I hypertension, while 109 
patients (78.4%) were classified as grade 
II hypertension. The combination of drugs 
used at UKI Hospital for the management 
of resistant hypertension uses 3 or 4 drugs. 
ACE-inhibitor / ARB +  CCB + thiazide 
combination diuretic is the most common 
combination
 A central ACE-inhibitor / ARB +  CCB 
+ alpha agonist is used in patients with CKD 
disease who are no longer urine producing, 
and a combination of 4 ACE-inhibitor / ARB 
+  CCB + thiazide diuretics + central alpha 
agonist.
119 patients with resistant hypertension 
used 3 drugs (85.9%) and 20 patients used 4 
drugs (14.4%).
Chronic kidney disease is a disease 
that most often accompanies patients with 
resistant hypertension in the UKI Hospital, 
namely 71 patients (51.1%) other diseases 
such as diabetes mellitus, there are 46 
patients (33.1%), heart failure there are 35 
patients (25.2%), coronary heart disease. 
there were 39 patients (28.2%), stroke 
there were 3 patients (2.2%), and other 
diseases such as COPD, atrial fibrillation, 
nephrotic syndrome, cirrhosis of the liver, 
AV block, acute renal failure, dyslipidemia, 
supraventricular tachycardia, SLE, 
extrasystolic ventricle 24 patients (17.3%).
Methodology
This research is a descriptive study that 
explains the prevalence and comorbidities 
in the case of resistant hypertension at the 
UKI Hospital in 2019. The population is a 
large number of subjects who have certain 
characteristics that are tailored to the 
research objectives. The population in this 
study were all hypertension patients who 
were hospitalized at the UKI Hospital in 
2019. The sample data was taken from the 
Medical Record data of the UKI Hospital. 
The sampling method in this study used 
Consecutive Sampling. Consecutive 
Sampling is a sampling based on the 
fulfillment of the inclusion and exclusion 
criteria.
The inclusion criteria in this study were: 
Hypertension patients who were hospitalized 
during June-December 2019 at UKI Hospital 
and uncontrolled hypertensive patients after 
administering 3 types of anti-hypertensive 
drugs (ACE-i / ARB, CCB, diuretic).
 While the exclusion criteria in this study 
were: Hypertension patients who were not 
hospitalized during June-December 2019 
at UKI Hospital and hypertension sufferers 
who were controlled after administration 3 
types of anti-hypertensive drugs (ACE-i / 
ARB, CCB, diuretic).
Result
Of the 3,002 patients hospitalized at UKI 
Hospital in January - December 2019, 1,030 
patients were treated with hypertension. 
Resistant hypertension was found in 139 
patients, resulting in a prevalence rate of 
resistant hypertension in the UKI Hospital in 
2019 as much as 13.49%.
In 139 patients who had resistant 
hypertension at UKI Hospital, 70 patients 
were male (50.4%) and 69 patients were 
female (49.6%). Grouping based on age used 
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Age> 65 years is the age where resistant 
hypertension occurs the most in this study 
with an average age of 58 years. Age> 55 
years is the most common age with resistant 
hypertension cases.13 The average age of 
having resistant hypertension is 58.8 years. 12 
According to Persell, resistant hypertension 
occurs at an average age of 66.4 years14. 
According to Acharya et.al, resistant 
hypertension occurred at the age of 72.9± 
11.0 years. .11   This suggests that resistant 
hypertension is more common in the elderly.
In this study, the use of a combination of 
3 antihypertensive drugs was able to control 
blood pressure so that the combination of 4 
antihypertensive drugs was less  their use. 
Unlike the research conducted by Persell, the 
use of a combination of 3 antihypertensive 
drugs reached 43%, a combination of 4 
antihypertensive drugs reached 43.2%, 
and the use of a combination of ≥ 5 
antihypertensive drugs reached 13.8% . 14
This difference can occur because 
supervision at the inpatient installation 
can maintain the level of adherence to the 
consumption of antihypertensive drugs.
CKD is the most common comorbid 
disease in resistant hypertension cases in this 
study. This is different from the research of 
Acharya et.al, which shows that metabolic 
syndrome is the most common comorbid 
disease in resistant hyperthyma, reaching 
75% while CKD is only 20%.11 CKD 
accompanied by resistant hypertension, the 
prevalence rate reached 26% . 13
Conclusion
Of the 3,002 patients hospitalized at UKI 
Hospital in January - December 2019, 1,030 
patients were treated with hypertension. 
Resistant hypertension was found in 139 
patients, resulting in a prevalence rate of 
resistant hypertension in the UKI Hospital 
in 2019 as much as 13.49%. The results of 
Discussion
In this study, the prevalence rate of 
resistant hypertension was 13.49%. These 
results are in line with the prevalence rates 
available in other literature. According to 
Acharya et.al the prevalence of resistant 
hypertension reaches 9% and in elderly 
patients who come to primary health clinics 
it reaches 13% . 10,11 Based on data from 
Achelrod et.al, 20 observational studies of 
patients with resistant hypertension have a 
prevalence of 11.19% - 16.24% and 10.68% 
- 21.95% in 4 RCT studies. 7 Based on Lotufo 
et.al’s data, the prevalence of resistant 
hypertension reached 11% of 4,116 cases. 12 
According to Sarafidis et.al, the prevalence 
of resistant hypertension reached 9% - 12% 
. 13 According to Persell, the prevalence of 
resistant hypertension reached 12.8%.  14 
Some writers don’t have the same data as 
the prevalence rate of this study. According 
to ESC and ESH the prevalence rate of 
resistant hypertension does not reach 10% . 
15
Men who had resistant hypertension 
reached 50.4% and women 49.6%. Although 
the number of men is more affected by 
hypertension, this does not reflect that 
gender affects the incidence of resistant 
hypertension. Women with resistant 
hypertension reached 53.8%, not much 
different from men according to Persell.14 
Based on data from Lotufo et al. Women who 
had resistant hypertension reached 54.5% . 12 
Based on data from Achelrod et.al, women 
with resistant hypertension reached 52% . . 
7 All of this is different from Acharya et.al 
and Sarafidis et.al, men who have resistant 
hypertension are more than women. 11,13 
This research could not find a relationship 
between resistant hypertension and gender, 
but physiological factors and drug adherence 
levels can be confounding factors in the 
results of the study. . 7
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this study get the highest prevalence in male 
gender (50.4%). Based on age, the majority 
is obtained by age
> 65 years (32.4%) with an average age 
of 58 years and based on tension at admission 
to the hospital were categorized as grade 
II hypertension as many as 109 patients 
(78.4%) and chronic kidney disease was the 
most common disease among patients with 
resistant hypertension in RSU UKI.
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